Table S1. Adjusted odds ratios for the association between non-serous epithelial ovarian cancer and benign gynecologic conditionsa stratified by histologic subtypes.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Benign gynecologic condition** | **Histologic subtype** | **Cases (%)** | **Adjusted OR**b | **95% CI** |
| **Endometriosis** |  |  |  |  |
| *No* | *Mucinous* | 29 (93.6) | 1.00 | Referent |
| *Yes* |  | 2 (6.5) | 0.80 | 0.16-4.04 |
| *No* | *Endometrioid* | 41 (73.2) | 1.00 | Referent |
| *Yes* |  | 15 (26.8) | 5.17 | 2.30-11.64 |
| *No* | *Clear cell* | 17 (85.0) | 1.00 | Referent |
| *Yes* |  | 3 (15.0) | 2.60 | 0.62-10.92 |
| *No* | *Other*c | 82 (92.1) | 1.00 | Referent |
| *Yes* |  | 7 (7.9) | 2.29 | 0.89-5.93 |
| **PID** |  |  |  |  |
| *No* | *Mucinous* | 28 (90.3) | 1.00 | Referent |
| *Yes* |  | 3 (9.7) | 1.50 | 0.39-5.80 |
| *No* | *Endometrioid* | 55 (98.2) | 1.00 | Referent |
| *Yes* |  | 1 (1.8) | 0.20 | 0.02-1.68 |
| *No* | *Clear cell* | 18 (90.0) | 1.00 | Referent |
| *Yes* |  | 2 (10.0) | 1.89 | 0.39-9.24 |
| *No* | *Other*c | 84 (94.4) | 1.00 | Referent |
| *Yes* |  | 5 (5.6) | 1.18 | 0.42-3.31 |
| **Fibroid** |  |  |  |  |
| *No* | *Mucinous* | 19 (61.3) | 1.00 | Referent |
| *Yes* |  | 12 (38.7) | 1.28 | 0.54-3.03 |
| *No* | *Endometrioid* | 27 (48.2) | 1.00 | Referent |
| *Yes* |  | 29 (51.8) | 1.73 | 0.89-3.35 |
| *No* | *Clear cell* | 11 (55.0) | 1.00 | Referent |
| *Yes* |  | 9 (45.0) | 0.96 | 0.37-2.53 |
| *No* | *Other*c | 52 (58.4) | 1.00 | Referent |
| *Yes* |  | 37 (41.6) | 1.19 | 0.72-1.96 |
| **Ovarian Cyst** |  |  |  |  |
| *No* | *Mucinous* | 22 (71.0) | 1.00 | Referent |
| *Yes* |  | 9 (29.0) | 3.35 | 1.33-8.44 |
| *No* | *Endometrioid* | 47 (83.9) | 1.00 | Referent |
| *Yes* |  | 9 (16.1) | 0.85 | 0.34-2.10 |
| *No* | *Clear cell* | 17 (85.0) | 1.00 | Referent |
| *Yes* |  | 3 (15.0) | 1.04 | 0.27-4.04 |
| *No* | *Other*c | 81 (91.0) | 1.00 | Referent |
| *Yes* |  | 8 (9.0) | 0.81 | 0.35-1.87 |
| **# of gynecologic conditions** |  |  |  |  |
| *0* | *Mucinous* | 14 (45.2) | 1.00 | Referent |
| *1* |  | 12 (38.7) | 1.91 | 0.82-4.46 |
| *2+* |  | 5 (16.1) | 2.38 | 0.77-7.35 |
|  |  |  | ptrend = 0.078 |  |
| *0* | *Endometrioid* | 20 (35.7) | 1.00 | Referent |
| *1* |  | 21 (37.5) | 1.65 | 0.82-3.32 |
| *2+* |  | 15 (26.8) | 3.47 | 1.59-7.61 |
|  |  |  | ptrend = 0.002 |  |
| *0* | *Clear cell* | 9 (45.0) | 1.00 | Referent |
| *1* |  | 5 (25.0) | 0.71 | 0.23-2.21 |
| *2+* |  | 6 (30.0) | 2.66 | 0.87-8.11 |
|  |  |  | ptrend = 0.186 |  |
| *0* | *Other*c | 48 (53.9) | 1.00 | Referent |
| *1* |  | 29 (32.6) | 1.00 | 0.59-1.69 |
| *2+* |  | 12 (13.5) | 1.61 | 0.78-3.34 |
|   |  |   | ptrend = 0.325 |  |

OR: odds ratio, CI: confidence interval, dz.: disease, PID: pelvic inflammatory disease

a Diagnosis made >1 year before ovarian cancer diagnosis or interview.

b Fully adjusted model – adjusted for age at diagnosis (cases)/interview (control), study site, marital status, education, BMI, parity, tubal ligation, duration of oral contraceptive use, family history of breast or ovarian cancer, talc use, endometriosis, fibroid, PID, ovarian cyst. OR for # of gynecologic conditions not adjusted for endometriosis, fibroid, PID, ovarian cyst.

c Include mixed, NOS, other invasive epithelial ovarian carcinoma.